Paul Hudson, CEO of Novartis Pharma AG, discusses pricing, and expectations and dynamics around the company's star products including how Cosentyx (secukinumab) is sitting pretty in the rheumatology and psoriasis space, despite competition. Heart failure drug Entresto (sacubitril/valsartan), which is well on its way internationally, could potentially emerge as one of the most successful medicines ever launched by Novartis in India.
Novartis Pharma CEO On Star Products, Pricing And Rebates
Paul Hudson, CEO, Novartis Pharmaceuticals, was recently in India along with the executive leadership team of the Swiss multinational. In a wide-ranging exclusive interview with Scrip, he discussed Cosentyx’s edge over its competition, Entresto’s “incredibly bright future”, including in emerging markets like India, and why transparency on the scale of rebates in the US is "overdue."
